252 related articles for article (PubMed ID: 28445938)
1. Pirfenidone normalizes the tumor microenvironment to improve chemotherapy.
Polydorou C; Mpekris F; Papageorgis P; Voutouri C; Stylianopoulos T
Oncotarget; 2017 Apr; 8(15):24506-24517. PubMed ID: 28445938
[TBL] [Abstract][Full Text] [Related]
2. Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner.
Papageorgis P; Polydorou C; Mpekris F; Voutouri C; Agathokleous E; Kapnissi-Christodoulou CP; Stylianopoulos T
Sci Rep; 2017 Apr; 7():46140. PubMed ID: 28393881
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo.
Li C; Rezov V; Joensuu E; Vartiainen V; Rönty M; Yin M; Myllärniemi M; Koli K
Sci Rep; 2018 Jul; 8(1):10070. PubMed ID: 29968778
[TBL] [Abstract][Full Text] [Related]
4. Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy.
Mpekris F; Papageorgis P; Polydorou C; Voutouri C; Kalli M; Pirentis AP; Stylianopoulos T
J Control Release; 2017 Sep; 261():105-112. PubMed ID: 28662901
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of mechanical forces in tumors is related to hyaluronan content and tissue stiffness.
Voutouri C; Stylianopoulos T
PLoS One; 2018; 13(3):e0193801. PubMed ID: 29561855
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
7. Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.
Hagmeyer L; Treml M; Priegnitz C; Randerath WJ
Respiration; 2016; 91(4):327-32. PubMed ID: 27073887
[TBL] [Abstract][Full Text] [Related]
8. Anti-fibrotic effect of pirfenidone in muscle derived-fibroblasts from Duchenne muscular dystrophy patients.
Zanotti S; Bragato C; Zucchella A; Maggi L; Mantegazza R; Morandi L; Mora M
Life Sci; 2016 Jan; 145():127-36. PubMed ID: 26679108
[TBL] [Abstract][Full Text] [Related]
9. Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse.
Seniutkin O; Furuya S; Luo YS; Cichocki JA; Fukushima H; Kato Y; Sugimoto H; Matsumoto T; Uehara T; Rusyn I
Toxicol Appl Pharmacol; 2018 Jan; 339():1-9. PubMed ID: 29197520
[TBL] [Abstract][Full Text] [Related]
10. Improving drug delivery to solid tumors: priming the tumor microenvironment.
Khawar IA; Kim JH; Kuh HJ
J Control Release; 2015 Mar; 201():78-89. PubMed ID: 25526702
[TBL] [Abstract][Full Text] [Related]
11. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.
Mediavilla-Varela M; Boateng K; Noyes D; Antonia SJ
BMC Cancer; 2016 Mar; 16():176. PubMed ID: 26935219
[TBL] [Abstract][Full Text] [Related]
12. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Poletti V; Ravaglia C; Tomassetti S
Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-Derived Swelling of Solid Tumors, the Contribution of Collagen and Cancer Cells, and Implications for Cancer Therapy.
Voutouri C; Polydorou C; Papageorgis P; Gkretsi V; Stylianopoulos T
Neoplasia; 2016 Dec; 18(12):732-741. PubMed ID: 27886639
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.
Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y
Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors.
Didiasova M; Singh R; Wilhelm J; Kwapiszewska G; Wujak L; Zakrzewicz D; Schaefer L; Markart P; Seeger W; Lauth M; Wygrecka M
FASEB J; 2017 May; 31(5):1916-1928. PubMed ID: 28148565
[TBL] [Abstract][Full Text] [Related]
16. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Xaubet A; Serrano-Mollar A; Ancochea J
Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
[TBL] [Abstract][Full Text] [Related]
17. Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy.
Stylianopoulos T; Munn LL; Jain RK
Trends Cancer; 2018 Apr; 4(4):258-259. PubMed ID: 29606306
[TBL] [Abstract][Full Text] [Related]
18. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone: Clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis.
Bando M
Respir Investig; 2016 Sep; 54(5):298-304. PubMed ID: 27566376
[TBL] [Abstract][Full Text] [Related]
20. Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models.
Mpekris F; Papaphilippou PC; Panagi M; Voutouri C; Michael C; Charalambous A; Marinov Dinev M; Katsioloudi A; Prokopi-Demetriades M; Anayiotos A; Cabral H; Krasia-Christoforou T; Stylianopoulos T
ACS Nano; 2023 Dec; 17(24):24654-24667. PubMed ID: 38054429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
